drugset
drugset / Trial / NCT01207973

Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee

NCT01207973 ↗

Phase 1 Terminated 36 enrolled Boehringer Ingelheim
RandomizedSingle-groupDouble-blindTreatment

Summary

The objective of the study is to investigate the safety and tolerability of BI 113823 in male and female patients with osteoarthritis, following oral administration of BI 113823 with repeated rising doses.

Timeline

Start
2010-09
Primary completion
2011-01
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 113823 Unknown 50 mg Oral
Subject BI 113823 Unknown 100 mg Oral
Subject BI 113823 Unknown 200 mg Oral
Subject BI 113823 Unknown 350 mg Oral

Indications

osteoarthritis, knee